INTERBRI · CHINA MARKET ACCESS FOR MEDICAL DEVICES China-focused support. Clear scope. Accountable coordination.

Regulation Library

A continuously maintained archive of regulatory analysis, NMPA updates and practice Q&As — built to help you understand China's medical device oversight.

12Nov 2026
Regulatory Analysis9 min read

“China FDA website”? Finding the NMPA and the official portals

There is no current agency called China FDA. A guide to the NMPA, its official Chinese and English sites, and how regulatory responsibilities are divided.

12Nov 2026
Practical Guide11 min read

China medical device regulations PDF: official sources and version control

The two foundational texts, the regulatory hierarchy, where to download official PDFs, and how to check that an English copy is still current.

12Nov 2026
Regulatory Analysis12 min read

Provisions for Medical Device Registration and Filing (Decree No. 47) explained

Registration versus filing, Class I–III routes for imported devices, the China legal agent, Chinese-language dossiers, home-market evidence and clinical evaluation.

28Oct 2026
Practical Guide12 min read

How to register a medical device in China — a guide for foreign manufacturers

Classification, agent appointment, the seven-section dossier, testing and clinical evaluation, statutory review clocks, realistic timelines and cost structure.

28Oct 2026
Practical Guide10 min read

China legal agent for medical devices: duties, requirements and how to change one

The in-country representative under Decree 739 and Order 47 — distinct from distributors and EU authorized representatives.

28Oct 2026
Practical Guide11 min read

Clinical evaluation in China: exemptions, same-variety route and clinical trials

Three evidence routes under Decree 739 Articles 24–29 and Order 47 Articles 33–46 — and how to use foreign data.

28Oct 2026
Practical Guide10 min read

How to enter the Chinese medical device market: a practical roadmap

No registration, no import: roles, import compliance, special pathways and ten steps from assessment to first shipment.

26Oct 2026
Regulatory Analysis7 min read

Decree No. 739 in brief: what overseas manufacturers need to know

Core obligations of overseas registrants, China legal agents and post-market duties under the revised Regulations.

26Oct 2026
Regulatory Analysis7 min read

Classification Catalogue dynamic adjustments explained

How the catalogue is updated, and what adjustments mean for products already on or entering the market.

24Oct 2026
NMPA Announcements6 min read

UDI rollout tracker

Implementation batches, product scope and a step-by-step checklist for overseas manufacturers.

22Oct 2026
Practice Q&A8 min read

Post-market obligations & vigilance Q&A

Ongoing duties, vigilance reporting timelines and recall coordination — in practical terms.

19Oct 2026
NMPA Announcements6 min read

Announcements & guidance tracker

Which official publications matter, how they affect exporters, and a four-step framework you can copy.

12Oct 2026
Practice Q&A8 min read

Submission practice Q&A

Classification, legal agents, dossiers, foreign clinical data, renewals and changes — answered from practice.

Content in this library is a general summary and does not constitute legal advice. The official NMPA publications and current regulations always prevail.

Want a clearer route into the Chinese market?

Beyond the library, we would be glad to discuss your product and your China market plan.